title: NGcGM3/VSSP vaccine as treatment for melanoma patients.
abstract: Gangliosides are glycosphingolipids that are present in the plasma membranes of vertebrates and are involved in multiple cellular processes. In the Center of Molecular Immunology an NGcGM3 ganglioside based vaccine has been developed and is conceptualized as a targeted therapy in cancer. NGcGM3/VSSP vaccine had been used as treatment of metastatic melanoma patients and had showed to be safe and immunogenic. The treatment improved antitumoral response or maintain the response obtained with previous onco-specific treatment as chemotherapy. The results indicate that the vaccine improved overall survival of metastatic melanoma patients after first line-chemotherapy. The clinical trial ongoing currently will allow corroborating these results.
authors: Clinical Trials Division; Center of Molecular Immunology; Havana, Cuba.
authors: Kirenia
authors: K
authors: Pérez
authors: Marta
authors: M
authors: Osorio
authors: Julio
authors: J
authors: Hernández
authors: Adriana
authors: A
authors: Carr
authors: Luis Enrique
authors: LE
authors: Fernández
mesh_terms: D019496:Cancer Vaccines / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D005679:G(M3) Ganglioside / Q000008:administration & dosage*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008545:Melanoma / Q000628:therapy*; D011510:Proteolipids / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D005679:G(M3) Ganglioside; D011510:Proteolipids; C020485:proteoliposomes
keywords: NGlycolylated ganglioside; clinical trial; metastatic melanoma; vaccine